-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

Benzinga·08/05/2026 20:58:37
Listen to the news
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.